These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30377915)

  • 1. ASO Author Reflections: Predicting High-Risk Oncotype DX Recurrence Scores as a Strategy for Assessing Neoadjuvant Chemotherapy Eligibility.
    Newman L
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):683-684. PubMed ID: 30377915
    [No Abstract]   [Full Text] [Related]  

  • 2. Oncotype DX
    Pease AM; Riba LA; Gruner RA; Tung NM; James TA
    Ann Surg Oncol; 2019 Feb; 26(2):366-371. PubMed ID: 30542840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score.
    Yardley DA; Peacock NW; Shastry M; Burris HA; Bechhold RG; Hendricks CB; Yoshizawa CN; Sing AP; Hainsworth JD
    Breast Cancer Res Treat; 2015 Nov; 154(2):299-308. PubMed ID: 26507191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer.
    Soran A; Bhargava R; Johnson R; Ahrendt G; Bonaventura M; Diego E; McAuliffe PF; Serrano M; Menekse E; Sezgin E; McGuire KP
    Breast Dis; 2016 Jul; 36(2-3):65-71. PubMed ID: 27662272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the role of pharmacy technicians in reviewing the eligibility for Oncotype DX genomic test and the impact of the test on treatment plans in breast cancer patients.
    Cheng V; Markarian A; de Lemos ML; Schaff K
    J Oncol Pharm Pract; 2019 Jul; 25(5):1167-1173. PubMed ID: 30348071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of the 21-Gene Recurrence Score in a Diverse Breast Cancer Patient Population: Development of a Clinicopathologic Model to Predict High-Risk Scores and Response to Neoadjuvant Chemotherapy.
    Park KU; Chen Y; Chitale D; Choi S; Ali H; Nathanson SD; Bensenhaver J; Proctor E; Petersen L; Loutfi R; Simonds A; Kuklinski M; Doyle T; Dabak V; Cole K; Davis M; Newman L
    Ann Surg Oncol; 2018 Jul; 25(7):1921-1927. PubMed ID: 29679201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncotype DX
    Rath MG; Uhlmann L; Fiedler M; Heil J; Golatta M; Dinkic C; Hennigs A; Schott S; Ernst V; Koch T; Sohn C; Brucker C; Rom J
    Arch Gynecol Obstet; 2018 Feb; 297(2):443-447. PubMed ID: 29236174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.
    Biroschak JR; Schwartz GF; Palazzo JP; Toll AD; Brill KL; Jaslow RJ; Lee SY
    Breast J; 2013; 19(3):269-75. PubMed ID: 23614365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
    Tsai ML; Lillemoe TJ; Finkelstein MJ; Money JE; Susnik B; Grimm E; Kang SH; Swenson KK
    Clin Breast Cancer; 2016 Feb; 16(1):45-50. PubMed ID: 26385397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.
    D'Alfonso TM; van Laar RK; Vahdat LT; Hussain W; Flinchum R; Brown N; John LS; Shin SJ
    Breast Cancer Res Treat; 2013 Jun; 139(3):705-15. PubMed ID: 23774991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.
    Cheung PS; Tong AC; Leung RC; Kwan WH; Yau TC
    Hong Kong Med J; 2014 Oct; 20(5):401-6. PubMed ID: 24948666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
    Iwata H; Masuda N; Yamamoto Y; Fujisawa T; Toyama T; Kashiwaba M; Ohtani S; Taira N; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Shibahara Y; Sasano H; Yamaguchi T; Sakamaki K; Bailey H; Cherbavaz DB; Jakubowski DM; Sugiyama N; Chao C; Ohashi Y
    Breast Cancer Res Treat; 2019 Jan; 173(1):123-133. PubMed ID: 30242578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of PONDx, a prospective multicenter study of the Oncotype DX
    Curtit E; Vannetzel JM; Darmon JC; Roche S; Bourgeois H; Dewas S; Catala S; Mereb E; Fanget CF; Genet D; Forest AM; Bernier C; Pivot X
    Breast; 2019 Apr; 44():39-45. PubMed ID: 30634106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
    Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
    Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
    Dodson A; Okonji D; Assersohn L; Rigg A; Sheri A; Turner N; Smith I; Parton M; Dowsett M
    Breast Cancer Res Treat; 2018 Feb; 168(1):249-258. PubMed ID: 29128896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applying new Magee equations for predicting the Oncotype Dx recurrence score.
    Sughayer M; Alaaraj R; Alsughayer A
    Breast Cancer; 2018 Sep; 25(5):597-604. PubMed ID: 29691722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer.
    Felts JL; Zhu J; Han B; Smith SJ; Truica CI
    Breast J; 2017 Nov; 23(6):677-686. PubMed ID: 28097781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical roundtable monograph: a multidisciplinary approach to the use of oncotype DX in clinical practice.
    Gradishar WJ; Hansen NM; Susnik B
    Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-7. PubMed ID: 19536946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany.
    Lux MP; Nabieva N; Hildebrandt T; Rebscher H; Kümmel S; Blohmer JU; Schrauder MG
    Breast; 2018 Feb; 37():89-98. PubMed ID: 29128582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Economic assessment of the routine use of Oncotype DX® assay for early breast cancer in Franche-Comte region].
    Nerich V; Curtit E; Bazan F; Montcuquet P; Villanueva C; Chaigneau L; Cals L; Méneveau N; Dobi E; Altmotlak H; Algros MP; Choulot MJ; Nallet G; Limat S; Mansion S; Pivot X
    Bull Cancer; 2014; 101(7-8):681-9. PubMed ID: 25091650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.